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Clinical Research
Parenteral nutrition (PN) is a standard therapy for hospitalized 
patients who are malnourished or at risk for malnutrition and 
are unable to meet nutrition requirements via the oral or enteral 
route. Hospitalized patients who receive PN are at increased 
risk of infection, and the use of intravenous fat emulsion (IVFE) 
may be an additional risk factor for infectious complications.1-4 
IVFEs are used in PN as a source of calories and essential fatty 
acids. They are also precursors of eicosanoids that affect plate-
let aggregation, immune function, and inflammation.3-5 The use 
of IVFE, however, may be associated with a potential increase 
in infectious complications, especially bloodstream infec-
tions.1,3,4 Currently available IVFEs in the United States are 
made from soybean oil that supplies long-chain triglycerides 
(LCTs).3,4,6 The slightly alkaline, isotonic IVFE solution pro-
vides a favorable milieu for microbial growth including gram-
positive, gram-negative, and fungal microorganisms.3,7,8 Based 
on in vitro studies that have shown prolific microbial growth in 
IVFE, the Centers for Disease Control (CDC) has recom-
mended a maximum IVFE infusion time of no longer than 12 
hours.3,8,9 Furthermore, LCTs in IVFEs may have immunosup-
pressive effects, therefore concerns have been raised regarding 
the possibility of increased infection risk with IVFE infusion.3 
It has been postulated that the reticuloendothelial system (RES) 
function may become impaired when high amounts of infused 
IVFE compete with microorganisms for clearance and LCT 
deposition in the liver diminishes the ability of Kupffer cells to 
sequester bacteria.3,6,10,11 IVFE may also interfere with neutro-
phil and macrophage function thereby decreasing the ability to 
fight infections.4 Despite these concerns, there is a lack of clear 
data to support the role IVFE plays with respect to infectious 
risk.12-15 Whereas some clinical studies reported a higher inci-
dence of infections in patients who received PN with IVFE as 
compared to PN without IVFE, although the difference was not 
statistically significant,15-16 others reported that IVFE may pos-
sibly reduce the occurrence and severity of infections by 
improving the activity of lymphocytes and cytokines.17-18
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Abstract
Background: Increased risk for infection has been associated with the administration of intravenous fat emulsion (IVFE). Typically, IVFE is 
infused daily as part of the parenteral nutrition (PN) regimen. However, a national IVFE shortage in 2010 compelled institutions to restrict 
administration to nondaily. This retrospective study evaluated the rate of infections associated with the nondaily as compared to daily IVFE 
infusion in hospitalized adult patients. Methods: Patients in the study group received nondaily IVFE during the shortage period, and patients 
in the control group received daily IVFE. The primary outcomes were the development of catheter-related bloodstream infections (CR-BSIs) 
or any bloodstream infection (BSI). Secondary outcomes were the development of respiratory, urinary, wound, or other infections. Results: 
Included in the study were 52 patients, 33 patients in the study group and 19 patients in the control group. There were no CR-BSIs reported. 
BSIs occurred in 1 patient in the study group. The total number of infections and urinary tract infections (UTIs) per 1000 catheter days were 
not different between the 2 groups (45.28 vs 21.24, P = .203) and (24.39 vs 5.525, P = .099), respectively. Survival analyses showed no 
difference between the 2 groups for the time to first infection (11.24 vs 6.59 days, P = .30) and time to first UTI (11.97 vs 7 days, P = .093), 
respectively. Conclusions: Nondaily vs daily IVFE infusion did not have a significant effect on the risk of infection or time to development 
of infection; however, results are limited due to the small sample size. Large prospective randomized clinical trials are needed to further 
evaluate the effect of daily as compared to nondaily IVFE infusion on infectious complications. (Nutr Clin Pract. 2013;28:737-744)
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The standard practice is to administer IVFE daily with PN, 
unless it is otherwise contraindicated or not required to meet 
caloric needs. A national shortage of IVFE in 2010-2011 com-
pelled healthcare institutions to conserve IVFE supplies by 
providing IVFE less frequently.19 At our institution, patients 
who weighed ≥30 kg received IVFEs twice weekly during the 
shortage period. To date, no published studies have evaluated 
the rate of infectious complications in patients who receive 
daily IVFE as compared to nondaily/intermittent IVFE infu-
sions. The aim of this study was to retrospectively evaluate the 
effects of nondaily vs daily IVFE infusion on the development 
of infectious complications in hospitalized adult patients who 
received IVFE as part of their PN therapy.
Methods
This was a retrospective evaluation of the effects of nondaily 
vs daily IVFE infusion on infectious complications in hospi-
talized adult patients at a tertiary care health system. 
Hospitalized patients over 18 years of age who weighed at 
least 30 kg and received PN with at least 1 dose of IVFE via 
a peripherally inserted central catheter (PICC) during the 
period between May 19, 2010, and August 31, 2011, were 
included in the study. The study group included patients who 
received IVFE twice weekly (nondaily IVFE) during the 
period of IVFE shortage, between May 19, 2010, and March 
30, 2011. The control group included patients who received 
daily IVFE following the end of the shortage between March 
31, 2011, and August 31, 2011. Patients were excluded if 1 or 
more of the following criteria were met: pregnant females; 
received PN prior to hospital admission; located in or trans-
ferred from an intensive care unit (ICU); received propofol, 
clevidipine, or liposomal amphotericin B; received antibiot-
ics or antifungals for longer than 48 hours prior to PN initia-
tion; received antibiotics or antifungals during PN therapy 
without documented infection; were immunosuppressed or 
received immunosuppressive agents (Table 1); received PN 
through an intravenous (IV) catheter other than a PICC; 
received cycled (<24 hours) IVFE infusion; received blood 
transfusions; had severe liver disease (Table 2); and/or were 
treated with dialysis.
Patients were identified using electronic patient medical 
records and pharmacy data systems. Collected data included 
demographics (age, gender, race, weight, and height); hospital 
length of stay; indication for PN; duration of IV catheter place-
ment before PN or IVFE initiation; IV catheter type; number of 
catheter lumens; signs of infection (body temperature over 
38°C, elevated white blood cell count, and absolute neutrophil 
count); serum glucose concentrations; total daily calories from 
PN; daily IVFE dose (ml); and the duration of IVFE treatment. 
Microbiology data included all positive cultures including 
specimen type, microbiological organism, and reported sensi-
tivities for positive cultures. In addition, antimicrobial regi-
mens were documented for each positive culture (Table 2).
The primary outcomes were the development of catheter-
related bloodstream infections (CR-BSIs) or any bloodstream 
infection (BSI). Secondary outcomes included the develop-
ment of pneumonia, urinary tract infections (UTIs), wound 
infections, the composite of any other infection, and the time to 
development of first infection. The study was approved by the 
Institutional Review Board.
Statistics
A previously published study in which infectious complica-
tions were evaluated when IVFE was withheld for the first 
7-10 days of PN in surgical ICU patients provided the basis for 
the power analysis.6 A sample size of 253 patients in each 
group was deemed necessary to detect a difference in incidence 
of infectious complications between the 2 groups, with 80% 
power and a 2-sided significance level of .05. Data were ana-
lyzed from the first day of PN initiation and up to 30 days or 
until patient discharge from the hospital, whichever came first. 
Descriptive statistics were used for comparisons between the 2 
groups. Student’s t test, Wilcoxon rank sums and negative 
binomial distribution were used for continuous data analysis. 
Chi-square and Fisher’s exact tests were used for analysis of 
categorical variables. Time to first infection was analyzed 
using the Kaplan–Meier survival analysis. A regression analy-
sis of survival data was performed to evaluate the effects of 
variables on hazard rates. SAS software (SAS Institute Inc, 
Cary, NC, USA) was used for data analysis.
Table 1. Definitions: Immunosuppressive Conditions and Agents.
Immunosuppressive Conditions Immunosuppressive Agents
● Cancer and/or receiving chemotherapy ● Corticosteroids
● Transplantation ● Calcineurin inhibitors (eg, cyclosporine, tacrolimus)
● Antimetabolic agents (eg, methotrexate, sirolimus, azathioprine, mercaptopurine)
●  Biological agents (eg, daclizumab, infliximab, etanercept, vincristine, vinblastine, 
paclitaxel, doxorubicin, daunorubicin, bleomycin)
● HIV/AIDS
● Systemic lupus erythematosus
● Rheumatoid arthritis
● Psoriasis
● Systemic bacterial/fungal infection  
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Results
A total of 612 patients were evaluated of whom 52 patients met 
the inclusion criteria. These included 33 patients in the study 
group who received nondaily IVFE, and 19 patients in the con-
trol group who received daily IVFE. Of those excluded, 306 
patients met at least 1 exclusion criteria and the other 254 
patients met at least 2 exclusion criteria. The most common 
reason for exclusion was the administration of antibiotics for 
longer than 48 hours prior to PN initiation (Table 3).
Overall baseline characteristics were similar between the 2 
groups (Table 4) with the following exceptions: patients in the 
study group had significantly fewer IVFE treatment days (1.48 
vs 6.47 days, P < .0001) and more catheter days prior to IVFE 
initiation (1.85 vs 0.53 days, P = .0016), as compared to the 
control group, respectively. The mean number of catheter 
lumens was also significantly higher in the study group as com-
pared to the control group (2.27 vs 1.94, respectively, P = .034). 
Nutrition data were similar between the 2 groups (Table 5), 
although the study group received significantly lower average 
daily lipid calories as compared to patients in the control group, 
3.68 vs 4.96 kcal/kg/day respectively, P = .012. 
BSIs occurred in 1 patient in the study group (Table 6). 
There were no CR-BSIs. Overall, 14 patients (26.9%) had doc-
umented infections, including 10 patients in the study group 
(30.3%) and 4 patients in the control group (21.1%) who 
developed at least 1 type of infection. Of all infections, 76.5% 
occurred in the study group as compared to 23.5% in the con-
trol group. Eight patients developed UTIs, of whom 7 patients 
were in the study group. One patient in the control group devel-
oped pneumonia.
The number of infections per 1000 catheter days was not 
significantly different between the study and control groups 
(45.28 vs 21.24, respectively, P = .203). The number of UTIs 
per 1000 catheter days was also not significantly different 
between the study and control groups (24.39 vs 5.525, respec-
tively, P = .099).
Survival analyses for time to first infection (11.24 vs 6.59 
days, P = .30) (Figure 1) and time to first UTI (11.97 vs 7 days, 
P = .093) (Figure 2) showed no difference between the study 
and control groups, respectively. However, there was a trend 
toward significance for time to first UTI. Average serum glu-
cose concentrations, time to IVFE initiation, and mean IVFE 
calories did not have an effect on infectious complications and 
were not shown to be predictors of infection (P = .56, .72, and 
.87, respectively) for either group.
Survival analysis for time to any infection in relation to the 
number of catheter lumens showed no statistically significant 
difference when accounting for nondaily vs daily IVFE (HR = 
2.086, 95% CI = 0.0671-6.483, P = .204). When all infections 
were considered in aggregate (HR = 2.338, 95% CI = 0.811-
6.742, P = .116) (Figure 3). Similarly, there was no significant 
Table 2. Pertinent Study Definitions.
Term Definition
Severe liver diseases ● Documented hepatitis
● Documented alcohol and drug induced liver disease
● Documented cirrhosis
● Clinically significant elevations in LFTs as follows:
○  Increased serum alanine aminotransferase (ALT; normal range 7-35 IU/L), aspartate 
aminotransferase (AST; normal range 8-30 IU/L), alkaline phosphatase (ALP; normal range 
30-130 IU/L) concentrations at least 3 times the upper limit of normal in patients with previously 
normal values, OR
○  If baseline (at least 2 measurements performed during the current hospital period) serum 
ALT, AST, or ALP concentrations were elevated, then increased serum ALT, AST, or ALP 
concentrations at least 3 times higher than baseline concentrations OR
○  Any increased serum ALT, AST, or ALP concentrations associated with increased total bilirubin 
(normal range 0.2-1.2 mg/dL) ≥ 2.5 mg/dL
Catheter-related bloodstream 
infection (CR-BSI)
●  Positive intravenous catheter tip cultures or a positive blood culture drawn from the catheter consistent with 
a simultaneously drawn peripheral blood culture and a duration of antibiotic therapy for at least 10 days
Bloodstream infection ● Positive blood culture and a duration of antibiotic therapy for at least 10 days
Wound infection ●  Positive culture from the surgical site or a positive pelvic fluid culture and a duration of antibiotic 
therapy for at least 7 days
Respiratory tract infection ● Positive sputum culture and a duration of antibiotic therapy for at least 7 days
Urinary tract infection ● Positive urine culture and duration of antibiotic therapy for at least 3 days
Intra-abdominal infection ●  Positive peritoneal fluid culture or a positive abdominal abscess culture and a duration of antibiotic 
therapy for at least 10 days
“Other” infections ●  Positive cultures from “other” sites managed with appropriate antibiotics for an appropriate length of 
time
LFT, liver function tests.
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difference in the time to UTI in relation to the number of cath-
eter lumens when accounting for nondaily vs daily IVFE (HR 
= 2.982, 95% CI = 0.685-12.99, P = .146) (Figure 4). However, 
there was a trend toward significance when considering all 
UTIs (HR = 3.657, 95% CI = 0.864-15.479, P = .078).
Discussion
The use of IVFE may be associated with a potential increase in 
infectious complications, especially BSIs, although it remains 
unclear whether infections are associated with PN infusion or 
more specifically IVFE.1,3,4,15,16
In this study, the frequency of IVFE administration did not 
statistically significantly increase the risk of infectious compli-
cations or the time to first infection. BSIs were observed in 1 
patient in the study group with a corresponding overall BSI 
rate of 0.02%. The low incidence of BSI is in contrast to data 
from a study that evaluated the impact of delaying IVFE 
administration for 7-10 days in 64 surgical ICU patients where 
CR-BSIs and BSIs were reported in 29.6% of patients.6 The 
higher incidence of CR-BSIs and BSIs in the latter study may 
be a reflection of the inclusion of critically ill patients who are 
at higher risk for infection as compared to our study that 
excluded critically ill patients, and the stringent criteria used 
for patient inclusion in our study.
In this study, no significant differences in pneumonia or 
CR-BSIs were found. Clinical studies of surgical patients who 
received IVFE reported increased risk of infectious complica-
tions including pneumonia, UTIs, and wound infections.6,16,20,21 
A study utilizing immunological data showed that the capacity 
of neutrophils to eradicate Streptococcus pneumoniae was neg-
atively impacted by the presence of IVFE.21 In a prospective 
study of 60 trauma patients, patients were randomized to 
receive PN therapy complete with IVFE or to PN therapy with 
IVFE withheld for the first 10 days of therapy; a significantly 
higher rate of pneumonia and line sepsis in patients who 
received IVFE was observed.20 One possible explanation for 
the observed differences between previous studies and our 
study may be that patients in our study received IVFE infused 
over 24 hours. Clinical studies of soybean-oil-based IVFE 
have shown that intermittent 10-hour IVFE infusion for 3 days 
decreases RES function by 40% whereas a continuous infusion 
did not negatively affect RES function.3,11 Considering the pos-
sible numerous mechanisms by which IVFE may increase the 
risk of infection, one may speculate that the lower infection 
rate observed in our study may be theoretically a reflection of 
the 24 hour IVFE infusions with possibly lesser impact on RES 
function.6,11,20,22
Although our study results showed no difference for the 
time to first UTI between the 2 groups, the rate of UTIs was 
higher in patients who received nondaily IVFE as compared to 
daily IVFE. Four of the 8 patients who developed a UTI were 
males who had bladder cancer and were admitted to the sur-
gery urology service for radical cystectomy. Three of those 4 
patients were in the study group. It is possible that the occur-
rence of UTI was associated with the patients’ urological con-
ditions and may not necessarily relate to IVFE infusion. In a 
prospective study of 140 patients who underwent urological 
interventions that included patients with benign prostate hyper-
plasia, bladder cancer, prostate cancer, and urolithiasis, the rate 
of UTI was reported at 21.4%.23 Because patients undergoing 
urological manipulations are at high risk of developing noso-
comial UTIs, patients in our study may have developed a UTI 
as a result of urology surgery regardless of IVFE infusion.
The higher rate of infection observed in the study group, 
although not significant, may be attributed to the higher num-
ber of intravenous catheter lumens. Although some studies 
have shown that single-lumen catheters are associated with a 
lower risk of infection than multilumen catheters, this observa-
tion has not been consistent in all studies.2,24-26 A prospective 
Table 3. Number of Patients Meeting Study Exclusion Criteria.
Exclusion Criterion
Number of 
Patients
Antibiotic > 48 hrs prior to PN initiation 271
Immunosuppressive agents 119
Cycled IVFE 93
Blood transfusion within 48 hrs of PN or during PN 89
Antifungal > 48 hrs prior to PN initiation 70
Chemotherapy 53
<1 dose of IVFE 31
Receipt of antibiotic during PN therapy without 
documented infection
23
Propofol, clevidipine, or liposomal amphotericin B 20
Severe liver disease/encephalopathy 19
Transferred from ICU 17
Dialysis 12
PN prior to hospital admission 11
Patient transferred from outside hospital with other 
exclusion criteria
10
Catheter other than PICC 9
No patient records 6
PICC placed at outside hospital 6
<18 years old 4
Located in ICU 4
Antifungal during PN therapy without documented 
infection
2
Pregnant 1
Prisoner 0
ICU, intensive care unit; IVFE, intravenous fat emulsion; PICC, peripher-
ally inserted central catheter; PN, parenteral nutrition. Out of 612 patients 
identified, 560 were excluded from the study. Study subjects may have 
met >1 exclusion criterion. Thus, the numbers depicted do not total the 
number of subjects excluded.
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surveillance study reported that each additional lumen signifi-
cantly increased the risk of CR-BSI by about 4.4 times (HR = 
3.3, P < .001).26 A meta-analysis reported that multilumen 
catheters were associated with only slightly higher risk of 
infection as compared to single-lumen catheters and concluded 
that multilumen catheters do not pose a significant risk factor 
for increased risk of BSIs.24 Although the impact of catheter 
lumens on the rate of BSI remains debatable, the CDC 
guidelines recommend using catheters with the lowest number 
of ports and lumens possible.2
Limitations
This study presents with limitations that include its retrospec-
tive design and small sample size. Although the study did not 
meet the predefined power calculation, the sample size is 
Table 4. Patient Demographics, Parenteral Nutrition Indicators, Catheter Data, & Clinical Indicators of Infection.
Demographic Nondaily IVFE (Study Group, n = 33) Daily IVFE (Control Group, n = 19) P Value
Gender
 Female n = 14 (42.42%) n = 11 (57.89%)  
 Male n = 19 (57.58%) n = 8 (42.11%) .28
Race
 Caucasian n = 28 (84.85%) n = 18 (94.74%)  
 African American n = 5 (15.15%) n = 1 (5.26%) .39
Age (yrs) 55.12 ± 16.35 62.17 ± 12.14  
 Mean ± SD [range] [21-85] [33-85] .11
Height (cm) 170.86 ±10.66 168.1 ±11.05  
 Mean ± SD [range] [142.24-193] [149.4-189] .38
Weight (kg) 77.1 82.7 .38
 Median [range] [47-162.39] [48.8-168.9]  
BMI (kg/m2) 25.65 29.6 .12
 Median [range] [17.94-57.81] [17.12-48.28]  
Percentage with BMI (kg/m2) > 30 30.3 42.11 .39
Hospital Length of Stay (days) 14 13  
 Median [range] [5-25] [4-29] .86
Indication for PN
 NPO n = 14 (42.42%) n = 10 (52.63%)  
 Malnutrition n = 5 (15.15%) n = 3 (15.79%)  
 Ileus n = 5 (15.15%) n = 3 (15.79%)  
 SBO n = 3 (9.09%) n = 0  
 Fistula n = 3 (9.09%) n = 0  
 Wound Infection n = 1 (3.03%) n = 0  
 GI bleed n = 1 (3.03%) n = 0  
 Elevated pancreatic enzymes n = 1 (3.03%) n = 1 (5.26%) .489
 Surgery n = 0 n = 2 (10.53%)  
Number PN days 5 ± 3.03 6.79 ± 6.01  
 Mean ± SD [range] [2-19] [1-27] .087
Number IVFE days 1.48 ± 0.75 6.47 ± 3.84  
 Mean ± SD [range] [1-4] [2-15] <.0001
Number of catheter lumens 2.27 ± 0.52 1.94 ± 0.52  
 Mean ± SD [range] [1-3] [1-3] .034
Number catheter days 8.69 ± 5.44 9.52 ± 6.74  
 Mean ± SD [range] [3-32] [3-29] .58
Catheter days prior to PN initiation 0.61 ± 0.9 0.47 ± 0.84  
 Mean ± SD [range] [0-3] [0-3] .59
Catheter days prior to IVFE initiation 1.85 ± 1.87 0.53 ± 0.84  
 Mean ± SD [range] [0-7] [0-3] .0016
Mean WBC count (k/mm3) 8.57 ± 2.69 9.3 ± 3.27 .39
 Mean ± SD [range] [5.42-14.53] [5.1-16.3]  
BMI, body mass index; GI, gastrointestinal; IVFE, intravenous fat emulsion; NPO, nil per os; PN, parenteral nutrition; SBO, small bowel obstruction; 
WBC, white blood cell; yrs, years. Catheter refers to central intravenous catheter (e.g. PICC line).
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Table 5. Nutrition Data.
Criterion Nondaily IVFE (Study Group, n = 33) Daily IVFE (Control Group, n = 19) P Value
Mean total kcal/kg/day
 Mean ± SD [range]
20.79 ± 6.04
[9.47-33]
24.22 ± 5.95
[13.13-39.85]
.0523
Mean PN kcal/kg/day
 Mean ± SD [range]
17.2 ± 4.96
[8.23-25.94]
19.26 ± 4.66
[10.24-30.4]
.13
Mean lipid kcal/kg/day
 Mean ± SD [range]
3.68 ± 1.78
[0.89-8.38]
4.96 ± 1.6
[2.77-9.45]
.012
Mean serum glucose while on PN (mg/dL)
 Mean ± SD [range]
126.7 ± 26.8
[100.9-206.3]
119.2 ± 25.39
[91.75-203.3]
.33
IVFE, intravenous fat emulsion; PN, parenteral nutrition.
Table 6. Infection Rate.
Criterion Nondaily IVFE (Study Group, n = 33) Daily IVFE (Control Group, n = 19) P Value
Primary outcomes
 Catheter-related bloodstream infection 0 0 —
 Bloodstream infection 1 (8%) 0 —
Secondary outcomes
 Pneumonia 0 1 (25%) —
 Urinary tract infection 7 (54%) 1 (25%) —
 Wound infection 3 (23%) 2 (50%) —
 Abdominal infection 2 (15%) 0 —
Total # of infections 13 (76.5% of all infections) 4 (23.5% of all infections) —
# of patients with infections 10 (30.3%) 4 (21.1%)  
# of infections per 1000 catheter days
 Mean ± SD [range]
45.28 ± 14.06
[24.64-83.20]
21.24 ± 11.44
[7.39-61.06]
.203
# of UTI per 1000 catheter days
 Mean ± SD [range]
24.39 ± 9.22
[11.63-51.16]
5.53 ± 5.53
[0.78-39.22]
.099
Figure 1. Survival analysis for time to first infection: Daily 
intravenous fat emulsion (IVFE) vs nondaily IVFE. The mean 
number of days for the nondaily IVFE group was 11.24 days, as 
compared to 6.59 days for the daily IVFE group, P = .3.
Figure 2. Survival analysis for time to first urinary tract infection 
(UTI): Daily intravenous fat emulsion (IVFE) vs nondaily IVFE. 
The mean number of days was 11.97 in the nondaily group, as 
compared to 7 days in the daily IVFE group, P = .093.
however comparable to those of other similar studies.6,16,20 The 
indication for PN therapy is included in Table 4. While the 
groups appear comparable, due to the large variety of indications 
and small sample sizes within each group, calculating signifi-
cance between the groups was not possible. It remains possible 
that differences between the groups exist, which is another 
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limitation to be considered. The strict inclusion criteria in this 
study can be viewed as a strength and limitation. Although the 
stringent inclusion criteria minimized the effects of confound-
ers on study results, they limited the sample size and reduced 
the external validity of the study as results may not necessarily 
be generalized to a larger population.
Conclusion
Nondaily vs daily IVFE infusion did not have a significant 
effect on the rate of infectious complications or the time to 
development of infection. Large prospective clinical studies 
are needed to further evaluate the impact of daily vs nondaily 
IVFE infusion on infectious complications.
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